Erlotinib
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Erlotinib |
| DrugBank ID | DB00530 |
| Brand Names (EU) | Tarceva |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 95.77% |
Approved Indication (EMA)
Non-small cell lung cancer (NSCLC) Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In patients with tumours without EGFR activating mutations, Tarceva is in
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Ewing sarcoma | 95.77% | DL |
| 2 | fibromatosis, gingival | 95.27% | DL |
| 3 | fibroma of lung | 95.12% | DL |
| 4 | hamartoma of lung | 95.07% | DL |
| 5 | lung benign neoplasm | 95.00% | DL |
| 6 | lung hilum carcinoma | 94.96% | DL |
| 7 | pulmonary sulcus neoplasm | 94.51% | DL |
| 8 | lung germ cell tumor | 94.51% | DL |
| 9 | lung cancer | 94.33% | DL |
| 10 | inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia | 93.34% | DL |
| 11 | junctional epidermolysis bullosa | 92.89% | DL |
| 12 | Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome | 92.60% | DL |
| 13 | ovarioleukodystrophy | 92.18% | DL |
| 14 | junctional epidermolysis bullosa, non-Herlitz type | 90.62% | DL |
| 15 | salivary gland type cancer of the breast | 90.05% | DL |
| 16 | dehydratase deficiency | 89.87% | DL |
| 17 | breast papillomatosis | 89.53% | DL |
| 18 | uterine corpus sarcoma | 89.02% | DL |
| 19 | giant adenofibroma of the breast | 88.84% | DL |
| 20 | diabetic mastopathy | 88.84% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.